title: Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population.
abstract: OBJECTIVE
  The International Association for the Study of Lung Cancer (IASLC) proposed a revision to the Union Internationale Contre le Cancer (UICC-6) staging system for non-small cell lung cancer. The goal of our study was to compare these systems in patients undergoing surgery for non-small cell lung cancer to determine whether one system is superior in staging operable disease.
  
  
  METHODS
  Pathologic stages in 1154 patients undergoing complete resection over a 9-year period were analyzed. Patients were assigned a stage based on both IASLC and UICC-6 systems. We tested for statistically meaningful differences between the two staging systems using the Wilcoxon signed rank test and the permutation test.
  
  
  RESULTS
  The IASLC system is more effective than the UICC-6 system at ordering and differentiating patients (P = .009). Application of the IASLC system resulted in 202 (17.5%) patients being reassigned to a different stage (P = .012), with the most common shifts occurring from IB to IIA and IIIB to IIIA. The 5-year and median survivals of the IASLC IIIA patients including those shifted from the UICC-6 IIIB were 37% and 35 months, respectively. Reclassifying UICC-6 IIIB to IASLC IIIA did not reduce survival for the newly characterized IIIA cohort.
  
  
  CONCLUSIONS
  Our data confirm that the proposed IASLC staging system is more effective at differentiating stage than the UICC-6 system. Reclassifying patients from UICC-6 IIIB to IASLC IIIA will shift some patients from a stage previously considered unresectable to a stage frequently offered surgical resection. Further study and validation of the IASLC system are warranted.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4095, USA.
authors.forename: Edmund S
authors.initials: ES
authors.lastname: Kassis
authors.forename: Ara A
authors.initials: AA
authors.lastname: Vaporciyan
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Swisher
authors.forename: Arlene M
authors.initials: AM
authors.lastname: Correa
authors.forename: B Nebiyou
authors.initials: BN
authors.lastname: Bekele
authors.forename: Jeremy J
authors.initials: JJ
authors.lastname: Erasmus
authors.forename: Wayne L
authors.initials: WL
authors.lastname: Hofstetter
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Komaki
authors.forename: Reza J
authors.initials: RJ
authors.lastname: Mehran
authors.forename: Cesar A
authors.initials: CA
authors.lastname: Moran
authors.forename: Katherine M
authors.initials: KM
authors.lastname: Pisters
authors.forename: David C
authors.initials: DC
authors.lastname: Rice
authors.forename: Garrett L
authors.initials: GL
authors.lastname: Walsh
authors.forename: Jack A
authors.initials: JA
authors.lastname: Roth
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000145:classification* / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000145:classification / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged